These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 16445378

  • 1. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T, Suzuki K, Yamana K, Tonegawa E, Wako K, Takahashi K.
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [Abstract] [Full Text] [Related]

  • 2. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T, Hashimoto Y, Takahashi K.
    Clin Cancer Res; 2004 Nov 01; 10(21):7121-6. PubMed ID: 15534082
    [Abstract] [Full Text] [Related]

  • 3. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [Abstract] [Full Text] [Related]

  • 4. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J.
    Eur Urol; 1997 Oct 01; 32 Suppl 3():78-80. PubMed ID: 9267790
    [Abstract] [Full Text] [Related]

  • 5. Endocrine therapy: where do we stand and where are we going?
    Schröder FH.
    Cancer Surv; 1991 Oct 01; 11():177-94. PubMed ID: 1841751
    [Abstract] [Full Text] [Related]

  • 6. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL, FinnProstate Group.
    J Urol; 2008 Sep 01; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [Abstract] [Full Text] [Related]

  • 7. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME.
    Expert Rev Anticancer Ther; 2008 Sep 01; 8(9):1495-508. PubMed ID: 18759700
    [Abstract] [Full Text] [Related]

  • 8. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM, Ryan CJ.
    Curr Opin Urol; 2009 May 01; 19(3):315-21. PubMed ID: 19342958
    [Abstract] [Full Text] [Related]

  • 9. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 10. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H, Messing EM, Chang C.
    Prostate; 2004 Dec 01; 61(4):332-53. PubMed ID: 15389811
    [Abstract] [Full Text] [Related]

  • 11. Endocrine therapy for prostate cancer.
    Labrie F.
    Endocrinol Metab Clin North Am; 1991 Dec 01; 20(4):845-72. PubMed ID: 1778180
    [Abstract] [Full Text] [Related]

  • 12. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 01; 22(2):229-41. PubMed ID: 18471782
    [Abstract] [Full Text] [Related]

  • 13. Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
    Geller J.
    J Androl; 1991 Apr 01; 12(6):364-71. PubMed ID: 1769904
    [Abstract] [Full Text] [Related]

  • 14. Endocrine therapy for prostate cancer.
    Sagalowsky AI.
    Spec Top Endocrinol Metab; 1985 Apr 01; 7():101-29. PubMed ID: 3914094
    [Abstract] [Full Text] [Related]

  • 15. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
    Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL.
    Clin Cancer Res; 2005 Jul 01; 11(13):4653-7. PubMed ID: 16000557
    [Abstract] [Full Text] [Related]

  • 16. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
    Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K.
    Int J Urol; 2004 Sep 01; 11(9):735-41. PubMed ID: 15379937
    [Abstract] [Full Text] [Related]

  • 17. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME.
    Nat Clin Pract Oncol; 2007 Apr 01; 4(4):236-44. PubMed ID: 17392714
    [Abstract] [Full Text] [Related]

  • 18. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN, Lush RM, Figg WD.
    Pharmacotherapy; 1996 Apr 01; 16(3):376-81. PubMed ID: 8726595
    [Abstract] [Full Text] [Related]

  • 19. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 01; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 20. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T, Nutahara K, Higashihara E.
    J Urol; 2008 Oct 01; 180(4):1342-7. PubMed ID: 18707699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.